U.S. Biotech Stock News

Piper Sandler’s decision to cut Twilio (TWLO) to a Neutral rating after two years of a more positive stance, citing valuation and potential growth slowdown by 2026, has sharpened investor focus on the stock. See our latest analysis for Twilio. Recent trading reflects mixed momentum, with a 22.21% 3 month share price return and a 26.92% 1 year total shareholder return, even as the latest downgrade and debate around Twilio’s growth outlook have tempered some of the earlier enthusiasm. If...

Why Firefly Aerospace is Suddenly in the Spotlight Firefly Aerospace (FLY) has drawn intense attention after multiple law firms announced class action lawsuits alleging misleading disclosures around demand for its Spacecraft Solutions and the readiness of its Alpha rocket program. The complaints center on statements tied to Firefly's August 2025 IPO and subsequent disclosures, following disappointing financial results and an Alpha Flight 7 mission issue that coincided with sharp share price...

Tenable Holdings recently announced a partnership with cybersecurity distributor Distology, adding its exposure management platform to Distology’s portfolio for channel partners across the UK, Europe, the Middle East, and Africa to help organizations assess and prioritize security risks across IT, cloud, and operational environments. This collaboration highlights how distributors are becoming central in getting unified exposure management tools into more regional markets, potentially...

Southwest Airlines (LUV) shares have been getting attention after recent performance metrics showed a 12.2% move over the past month and a 30.9% gain in the past 3 months, prompting fresh interest in its valuation. See our latest analysis for Southwest Airlines. That recent 30.9% 3 month share price return comes on top of a 1 year total shareholder return of 32%. This suggests momentum has picked up again after a quieter year to date and refocuses attention on whether the current US$42.48...

If you are wondering whether MasTec's recent share price puts it at a bargain or a stretch, you are in the right place to size up what that current price may mean for value. MasTec shares recently closed at US$236.35, with returns of 7.3% over the past week, 7.7% over the past month, 3.8% year to date and 61.4% over the past year, and 146.4% over three years and 193.5% over five years. These moves have kept MasTec on many investors' watchlists. They sit against a backdrop of ongoing interest...

National Energy Services Reunited Corp. recently presented at the Goldman Sachs Energy, CleanTech & Utilities Conference in Florida and has secured a multi-year unconventional fracturing contract in Saudi Arabia’s Jafurah field worth several billions over five years. This combination of greater investor visibility and a large, long-duration contract meaningfully extends the company’s revenue backlog and operational commitments in the MENA region. Next, we’ll examine how this multi-year...

If you are wondering whether Uber Technologies stock still offers value at around US$85.54 per share, it helps to look closely at what the current price might already be assuming about its future. The share price has returned 4.2% over the last 7 days, after a 6.3% decline over the last 30 days, and it currently sits on a 29.3% return over 1 year and 205.1% over 3 years. Recent news has focused on Uber’s push to deepen its mobility and delivery footprint, as well as ongoing attention on ride...

TETRA Technologies recently announced that its senior management participated in the 28th Annual Needham Growth Conference and the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference, hosting investor meetings and webcasts to outline its energy services, lithium, and low‑carbon technology initiatives. This heightened investor outreach, combined with growing attention on TETRA’s lithium and energy transition projects, has pushed the company into focus for higher‑risk,...

Energizer Holdings (ENR) is back on investor radars after recent share price moves, with the stock showing mixed performance over the past year and longer term. This is prompting fresh questions about how its fundamentals line up. See our latest analysis for Energizer Holdings. The recent 1 day share price return of 5.32% and 1 month share price return of 10.87% come after a much weaker patch, with the 1 year total shareholder return at a 39.06% loss. This suggests short term momentum is...

Citizens Financial Group (CFG) is back in focus after Barclays upgraded the stock, citing expectations around net interest margin trends, the buildout of its Private Bank, and ongoing transformation efforts. See our latest analysis for Citizens Financial Group. The Barclays upgrade lands on top of a strong run, with Citizens Financial Group’s share price at $62.14 and a 90 day share price return of 19.48%. The 1 year total shareholder return of 44.35% and 5 year total shareholder return of...

Public Service Enterprise Group (NYSE:PEG) is back in focus after New York State gave final approval to extend PSEG Long Island’s operations services agreement with LIPA through 2030, along with related leadership changes. See our latest analysis for Public Service Enterprise Group. The contract extension and leadership reshuffle come at a time when Public Service Enterprise Group’s 1 year total shareholder return is a 5.01% decline, while the 3 year and 5 year total shareholder returns of...

If you are wondering whether ACV Auctions at around US$8.55 is pricing in too much hope or not enough, you are in the right place to size up what the current market price might be implying. The stock has returned 5.0% over the last 7 days and 4.9% over the past month, although the 1 year return sits at a 57.9% decline, which may signal that expectations and perceived risk have shifted over time. Recent commentary around ACV Auctions has largely focused on its position in the online wholesale...

Agios Pharmaceuticals stock: recent performance context Agios Pharmaceuticals (AGIO) has seen mixed share performance recently, with a small move over the past week, a modest decline over the past month, and a sharper drop over the past 3 months. See our latest analysis for Agios Pharmaceuticals. At a share price of $27.47, Agios has a modest year to date share price return of 1.07%. However, the 90 day share price return of a 35.52% decline and the 1 year total shareholder return of a 21.78%...

For readers wondering whether Evercore's share price still offers value after a strong run, this article walks through what the current market price might be implying about the business. The stock last closed at US$374.02, with returns of 8.8% over 7 days, 12.8% over 30 days, 6.5% year to date and 37.8% over 1 year. The 3 year return is very large and the 5 year return is also very large. Recent coverage around Evercore has focused on its role as a major independent advisory firm and its...

If you are wondering whether Atlassian shares are offering fair value right now, you are not alone. This article will focus squarely on what the current price might mean for long term investors. The stock closed at US$158.36 recently, with returns of 2.3% year to date but a 36.1% decline over the past year, which raises questions about how the market is currently weighing its growth potential against risk. Recent attention on Atlassian has mainly centered on its collaboration and workflow...

In recent days, Fearnley Securities highlighted SFL Corporation’s bonds among its top picks, citing the company’s diversified exposure, solid charter backlog, and perceived credit strength. At the same time, SFL is drawing fresh interest from income-focused investors who value its long-term charter contracts, recurring cash flows, and emphasis on operational resilience over rapid growth. Next, we’ll examine how this renewed focus on SFL’s long-term cash flow stability and credit profile...

Recent analyst upgrades around Salesforce (CRM) and its agentic AI push have helped refocus attention on the stock, as investors weigh rising institutional interest against questions about how quickly new AI and data products scale. See our latest analysis for Salesforce. At a recent share price of US$262.90, Salesforce has seen a 9.35% 90 day share price return, while the 1 year total shareholder return of 18.56% decline contrasts with a 3 year total shareholder return of 80.48%. This...

In early January 2026, Perdoceo Education Corporation announced a new share repurchase program authorizing up to US$100 million of common stock buybacks through June 30, 2027, while confirming the prior plan had expired after repurchasing 2,500,000 shares for US$74.8 million. By pairing a fresh authorization with details of recent buybacks that retired nearly 3.9% of its shares, the company underscored an ongoing commitment to capital returns and balance sheet efficiency. Next, we’ll examine...

In recent days, Coinbase Global has received a Buy upgrade from Goldman Sachs and other upbeat analyst research, highlighting the company’s shift toward crypto infrastructure, subscription services, and a broader “everything exchange” model spanning crypto, equities, derivatives, and prediction markets. At the same time, Coinbase is pausing peso-to-USDC conversions and local banking rails in Argentina while continuing crypto-to-crypto trading, underscoring both its global expansion ambitions...

Dividend affirmation puts MetLife in focus for income investors MetLife (MET) is back on income investors’ radar after its board declared a first quarter 2026 common stock dividend of US$0.5675 per share, payable on March 10 to shareholders of record on February 3. See our latest analysis for MetLife. Recent trading has been relatively steady, with a 30 day share price return of 3.20% and a year to date share price return of 1.07%. The 5 year total shareholder return of 88.64% points to...

Why Campbell's (CPB) is catching investors' attention now Campbell's (CPB) has been under pressure, with the stock showing a 29% decline over the past year and weaker returns over the past 3 years and 5 years. At a last close of $27.01, Campbell's sits below its indicated intrinsic value estimate, with the data here pointing to a 55% intrinsic discount that may interest value focused investors. See our latest analysis for Campbell's. That picture of a 10.1% 1 month share price decline,...

If you are wondering whether Legend Biotech shares are pricing in too much hope or not enough, you are in the right place for a clear look at what you are actually paying for. The stock last closed at US$20.98, with returns of a 2.6% decline over 7 days, a 25.4% decline over 30 days, and a 37.5% decline over 1 year, which can change how investors think about both its growth potential and its risk. Recent coverage has focused on Legend Biotech's position in cell therapy, its partnerships with...

In late 2025, Interactive Brokers Group reported December metrics showing 3.384 million Daily Average Revenue Trades, client equity of US$779.9 billion, and client margin loan balances of US$90.2 billion, alongside a 32% year-over-year increase in accounts to 4.399 million. The company also disclosed that its individual and hedge fund clients, supported by low trading costs and global market access, collectively outperformed the S&P 500 Index in 2025, highlighting the platform’s role in...

Investors can buy low cost index fund if they want to receive the average market return. But if you invest in...